Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was named No. 3 in the Small Molecules category on The Medicine Maker Power List 2026, recognizing his leadership in innovative cancer drug development. Under his guidance, Ascentage Pharma has advanced novel therapies like olverembatinib and lisaftoclax, addressing unmet medical needs in cancer treatment. The company is conducting multiple global Phase III trials and has achieved dual stock listings in Hong Kong and the U.S. Dr. Yang’s recognition highlights Ascentage’s impact on global oncology innovation and its commitment to developing new cancer therapies.
Toescoin, a memecoin on the Solana blockchain, announced talks with a major Japanese venture capital firm interested in investing up to $250,000 over time. This engagement aims to provide both funding and strategic support as Toescoin expands its pre...
An Ethereum Foundation experiment using AI agents discovered a genuine remote crash vulnerability in Ethereum validator software's GossipSub networking component. This bug could cause validator software to crash remotely, posing a denial-of-service r...
The Direxion Daily S&P 500 Bull 3X Shares (SPXL) aims to deliver three times the S&P 500's daily returns using derivatives and daily leverage resets. While it can amplify gains in strong, steady bull markets, its daily compounding and volatility can ...
Paramount Skydance's acquisition of Warner Bros. Discovery faces regulatory hurdles across the U.S., California, Brussels, and the U.K., each with different concerns. The U.S. Justice Department approved the deal, but a California court paused it ove...
A new patent application reveals a quantum AI project creating humanoid robots that can carry a person's 'digital DNA' to live alongside humans for centuries. This technology, part of a federally registered clinical trial, allows families to preserve...
